Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669301 · ClinicalTrials.gov registry record · NA
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
A NA study of Cognitive Impairment and Cancer-related Problem/Condition, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT04669301: Completed NA study of Cognitive Impairment and Cancer-related Problem/Condition, sponsored by University of Rochester.
NCT04669301 is a NA study of Cognitive Impairment and Cancer-related Problem/Condition that has completed, run by University of Rochester. The registered enrollment target is 72 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04669301, a NA study of Cognitive Impairment and Cancer-related Problem/Condition, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and subsequently test the ability of MAAT to improve or maintain cognition for older adults with breast cancer receiving adjuvant chemotherapy.
Primary Outcome
The Functional Assessment of Cancer Therapy-Cognition tool is a 50-question tool that evaluates memory and mental function in the past 7 days. The range of scores for the tool are 0 to 200 with higher scores generally indicating worse health outcomes.
Conditions Studied
Interventions
- BEHAVIORAL MAAT-G
- BEHAVIORAL Supportive therapy (time and attention control)
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-04-02 |
| Est. Completion | 2024-08-30 |
| Phase | NA |
What the finished NCT04669301 record still lists
NCT04669301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which MAAT-G is the first listed.
NCT04669301 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04669301 about?
NCT04669301 is a clinical study titled "Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II". Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising trea...
What is the current status of trial NCT04669301?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2021-04-02. Estimated completion is 2024-08-30.
What conditions does trial NCT04669301 study?
This clinical trial studies the following conditions: Cognitive Impairment, Cancer-related Problem/Condition.
What interventions are being tested in trial NCT04669301?
The interventions under investigation include: MAAT-G (BEHAVIORAL), Supportive therapy (time and attention control) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04669301?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669301 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04669301's enrollment target sits among peer trials
72 58th of 105 higher than 46 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI